Drugs / CXL-1020
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01092325 | Jun 2009 → May 2010 | heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01096043 | Apr 2010 → Feb 2012 | systolic heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CXL-1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01096043 ↗ |
| Modality | Other / unclassified | “Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020)” PMID 24107588 ↗ Oct 2013 |
| Route | Intravenous | “Intravenous infusion of one of 3 active dosages of CXL-1020” NCT01092325 ↗ |